Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Study Uncovers Mode Of Action Of Enzyme Linked With Several Types Of Cancer
Scientists at the Institute for Research in Immunology and Cancer (IRIC) of the Universitç© de Montrç©al have discovered a key mechanism used by cells to efficiently distribute chromosomes to new cells during cell multiplication. Published in the journal Molecular Cell, the study is the first to demonstrate that this mechanism relies on the polo kinase, an enzyme implicated in several cancers. Inhibiting this mechanism could be key to developing effective therapies to treat cancer.

Weight Determines The Future Cognitive Development Of Children Born Very Premature
Researchers of the Department of Neuroscience and Health Sciences of the University of Almería and Hospital Torrecárdenas are carrying out an assessment of the physical neuropsychological characteristics of children born before 32 weeks" gestation or whose weight is lower than 1500 grams -very premature-. The main aim of this project, coordinated by M Dolores Roldán Tapia, from the UAL, is to accurately define the origin of brain damage, so as to stimulate the affected area early thus causing the adequate cognitive and motric development of the individual.
News of the day
Meridian Bioscience Receives FDA Clearance For New Rapid Campylobacter Test
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for a new rapid test for Campylobacter, ImmunoCard STAT!® CAMPY. This new test provides fast and accurate detection of Campylobacter bacteria, one of the most common causes of diarrheal illness and the most common bacterial cause of foodborne illness in the United States. Approximately 20 million stool culture tests are conducted each year in the U.S. to detect the illness, known as Campylobacteriosis. Campylobacter is most often transmitted by poorly cooked poultry or person-to-person contact.
Sexual Health

Agendia Opens CLIA-Registered U.S. Genomics Laboratory

Agendia, a world leader in molecular cancer diagnostics, announced the opening of its U.S. clinical genomics laboratory in Huntington Beach, CA. The laboratory is fully-licensed and compliant with the Clinical Laboratory Improvements Amendments (CLIA) as administered by the Centers for Medicare and Medicaid Services (CMS). In addition to opening its U.S. cancer genomics laboratory, Agendia has over the past months made several key additions to its domestic-based senior executive team. The team consists of Dr. Richard Bender, Chief Medical Officer, Mr. Daniel Forche, Vice President of Sales & Marketing, Mr. Alan B. Carter, Vice President of Global Business Development, and pathologist Dr. Chynel Henning, Laboratory Director. "Our new genomics lab"s capacity will allow us to meet the increasing demand for MammaPrint across the United States and give physicians and patients optimal test result turnaround and unmatched service and support," noted Jan Groen, Ph.D., Chief Operating Officer. "This expansion places us in an excellent position to continue making advancements in molecular cancer diagnostics and equip oncologists with powerful tools to use in the fight against breast cancer." Dr. Bernhard Sixt, President and Chief Executive Officer, added, "the opening of the Huntington Beach laboratory and the appointment of our U.S.-based commercial team provide a strong basis for our U.S. operations and for Agendia"s next phase of growth. Our enhanced domestic capabilities will help us to further drive adoption of MammaPrint, and place us in an even better position to collaborate with a growing number of clinical, academic, and industrial partners here in the U.S." Dr. Bender has more than 30 years of medical and professional experience as a practicing oncologist and director of several oncology programs. Dr. Bender has served as Medical Director of the Hematology/Oncology Program at Quest Diagnostics, Director of Medical Oncology and Hematology at Kaiser Permanente Medical Group, Director of Strategic Development in Medical Oncology/Hematology at Johnson & Johnson, and as an investigator at the National Cancer Institute and Scripps Clinic and Research Foundation. Currently, Dr. Bender serves as an expert reviewer in oncology for the Medical Board of California, co-Editor of Anti-Cancer Drugs, an international journal on anti-cancer agents, and as a clinical instructor in medicine at the University of California, Irvine School of Medicine. Mr. Forche brings more than 18 years of sales, marketing and commercial leadership experience in the diagnostics arena. Prior to joining Agendia, Mr. Forche was the Senior Vice President of Sales and Marketing for Insight Health Corporation, a national leader in diagnostic imaging services. He also served as Vice President of Marketing at US LABS, an industry leader in cancer diagnostic and genomic testing services, and has held sales and marketing management roles at Ventana Medical Systems (now Roche) and Abbott Laboratories. Mr. Carter joins Agendia with 25 years of global business development experience from a number of top-tier life sciences companies such as BioTrove, Celera, Applied Biosystems, and Perkin Elmer. At Agendia, he oversees ongoing strategic alliances within the bio-pharmaceutical sector and collaboration with partners interested in Agendia"s expanding molecular diagnostics portfolio. Chynel Henning, M.D., Ph.D., FASCP, FCAP, joins Agendia with more than 30 years of experience as a laboratory director. He is currently also Director of National Cyto-Path Laboratories and Professional Pathology Medical Group Laboratory, both in Long Beach, California; and Director of the Laboratory and Department of Pathology at the Miracle Mile Medical Center, Los Angeles. Dr. Henning is a Fellow of the American Society of Clinical Pathologists and the College of American Pathologists. Ongoing research and development commitments continue to augment Agendia"s ability to accurately predict breast cancer recurrence and sub-typing, and help physicians tailor individual treatment plans to their patients. Agendia"s goal is to provide women with answers to crucial treatment questions, such as how their breast cancer will respond to targeted therapies or various chemotherapy regimens. Agendia B.V.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009